Compass Therapeutics (CMPX) FCF Margin (2024)

Compass Therapeutics (CMPX) reported FCF Margin of 1265.18% for Q2 2024.

Compass Therapeutics (CMPX) FCF Margin (2024) Analysis & Trends

Compass Therapeutics (CMPX) has 1 years of FCF Margin data on file, last reported at 1265.18% in Q2 2024.

For the quarter ending Q2 2024, FCF Margin changed N/A year-over-year to 1265.18%; the trailing twelve-month figure through Jun 2025 stood at 5331.18% (down 27976.0% YoY), and the FY2024 full-year result was 5282.24%, changed N/A from the prior year.
FCF Margin held at 1265.18% in Q2 2024.
In the past five years, FCF Margin ranged from a high of 1265.18% in Q2 2024 to a low of 1265.18% in Q2 2024.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	10.45%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	43.35%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	23.53%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Compass Therapeutics	395.17 Mn	200.48 Mn	-	-

Historic Data

Download Data

Date	Value
Jun 30, 2024	-1,265.18%